Tag:

ADHD

Latest Headlines

Latest Headlines

Do teens hear what we hear? FDA aims to find out in study of acne, ADHD ads

Acne remedies and ADHD drugs are big markets for the teen demographic--but how exactly are young consumers interpreting advertisements for these products? A soon-to-launch FDA study aims to find out exactly that.

With patent extension up for grabs, Shire agrees to test Vyvanse in preschoolers

To hear Shire tell it, there aren't many adequate and well-controlled drug studies in preschool-aged children with ADHD. But never fear, the company says: It's agreed to a written request by the FDA to investigate its ADHD drug Vyvanse in children aged 4 to 5, with a potential 6-month exclusivity boost for the drug on the line.

Pfizer, Forest and Lilly dominate top 10 ranking of psych meds

Psychiatric meds have been growth superstars for more than a decade, generating billions for their makers. But generics have flooded the playing field, and save a few select on-patent meds, today's top-selling psych meds, dollarwise, are lowercase copycats, not capital-letter brands.

UPDATED: Novartis recalls some Ritalin over packaging issue

Attention deficit hyperactivity disorder drugs like Ritalin have been on the FDA shortage list for a variety of reasons. Now add to that packaging problems which have led Novartis to recall nearly 22,000 bottles.

New attention disorder could equal a big new ADHD drug market. But is it legit?

There could be a new attention disorder on the block in the future--one that could open up a new patient pool for ADHD drugmakers Eli Lilly, Shire and others. But with pharma critics adept at pointing fingers at companies for "disease-mongering," it's one that could open up a new round of controversy, too.

Novartis-backed Neurovance bags $6.3M to focus on ADHD

Cambridge, MA's Neurovance has reeled in a $6.3 million extension to its earlier Series A, money it'll use to push forward with a promising nonstimulant treatment for attention deficit hyperactivity disorder.

Neos collects $15.5M from private investors to bring ADHD extended-release option to market

Texas oral drug delivery specialist Neos Therapeutics pulled in $15.5 million in a Series C round of financing to help propel its line of ADHD controlled-release treatments to the market.

Targacept shares crater after another program goes down in flames

After a steady drumbeat of setbacks over the past two years, the Winston-Salem, NC-based biotech says it will tamp down the last spade of dirt on TC-5619 after the therapy--which already failed a study for ADHD--flunked the primary as well as secondary endpoints in a Phase IIb study for schizophrenia.

ADHD experts worry that pharma ads drive too many kids to meds

Is the huge rise in attention-deficit hyperactivity disorder diagnoses a pharma coup or public-health boon?

Biomarker differentiates ADHD subtypes, offers clues for treatment

ADHD is one of the most frequently diagnosed psychiatric illnesses among children, and it's only growing more prevalent, yet subtypes of the disorder have proven tough to distinguish. Now researchers think they may have found a biomarker that does just that.